Oppenheimer analyst Jay Olson lowered his price target for Neurocrine to $105 from $140 after T-Force-GOLD missed the primary endpoint, sending the shares down on the loss of this important opportunity in Tourette syndrome. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.